Guiyang Xintian Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Guiyang Xintian Pharmaceutical Co Ltd working capital to net assets ratio. Guiyang Xintian Pharmaceutical Co Ltd (002873) has a Working Capital to Net Assets ratio of 12.5% as of March 2026. Working capital of CN¥156.90 Million (current assets of CN¥614.13 Million minus current liabilities of CN¥457.23 Million) is measured against net assets of CN¥1.26 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Guiyang Xintian Pharmaceutical Co Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Guiyang Xintian Pharmaceutical Co Ltd (2012–2025)
Working capital to net assets ratio of Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2025. This chart shows how Guiyang Xintian Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 12.5%, reflecting working capital of CN¥156.90 Million against net assets of CN¥1.26 Billion CNY. See Guiyang Xintian Pharmaceutical Co Ltd (002873) liquidity interval to measure how many days the company can operate on defensive assets alone.
Guiyang Xintian Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2012–2025)
Guiyang Xintian Pharmaceutical Co Ltd working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Guiyang Xintian Pharmaceutical Co Ltd assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 21.6% | CN¥270.84 Million | CN¥1.26 Billion | CN¥651.04 Million | CN¥380.20 Million | ▲ +10.2 pp |
| 2024 | 11.3% | CN¥135.43 Million | CN¥1.19 Billion | CN¥616.81 Million | CN¥481.38 Million | ▲ +4.1 pp |
| 2023 | 7.3% | CN¥81.00 Million | CN¥1.11 Billion | CN¥636.43 Million | CN¥555.42 Million | ▼ -2.9 pp |
| 2022 | 10.2% | CN¥115.24 Million | CN¥1.13 Billion | CN¥613.99 Million | CN¥498.75 Million | ▼ -6.1 pp |
| 2021 | 16.4% | CN¥145.59 Million | CN¥890.44 Million | CN¥586.83 Million | CN¥441.23 Million | ▼ -19.8 pp |
| 2020 | 36.1% | CN¥299.24 Million | CN¥828.30 Million | CN¥812.88 Million | CN¥513.64 Million | ▼ -0.2 pp |
| 2019 | 36.3% | CN¥257.36 Million | CN¥708.76 Million | CN¥590.06 Million | CN¥332.70 Million | ▼ -13.6 pp |
| 2018 | 49.9% | CN¥329.49 Million | CN¥660.59 Million | CN¥628.30 Million | CN¥298.81 Million | ▲ +1.9 pp |
| 2017 | 48.0% | CN¥298.60 Million | CN¥622.11 Million | CN¥504.05 Million | CN¥205.46 Million | ▲ +30.0 pp |
| 2016 | 18.0% | CN¥50.21 Million | CN¥279.21 Million | CN¥282.38 Million | CN¥232.18 Million | ▼ -1.0 pp |
| 2015 | 19.0% | CN¥43.07 Million | CN¥226.31 Million | CN¥234.10 Million | CN¥191.03 Million | ▼ -11.5 pp |
| 2014 | 30.5% | CN¥58.16 Million | CN¥190.50 Million | CN¥245.30 Million | CN¥187.14 Million | ▼ -0.4 pp |
| 2013 | 30.9% | CN¥48.67 Million | CN¥157.38 Million | CN¥216.88 Million | CN¥168.20 Million | ▼ -7.1 pp |
| 2012 | 38.0% | CN¥67.79 Million | CN¥178.44 Million | CN¥207.52 Million | CN¥139.73 Million | — |